THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today that it will sponsor this year’s Turning the Tide Against Cancer Through Sustained Medical Innovation national conference. Convened by the Personalized Medicine Coalition, the American Association for Cancer Research and Feinstein Kean Healthcare, the conference will be held on October 9, 2014 in Washington, DC.
The conference will focus on potential policy solutions to support the advancement of science and innovation, while addressing the issue of the rising cost of cancer care. Panel discussions, sessions and spotlight series by cancer community thought leaders are designed to expand upon the continued dialogue surrounding these topics and the shift to patient-centered cancer research and care.
As a company dedicated to utilizing and continuing scientific innovation to help patients and physicians make better, more informed decisions about cancer care, MolecularHealth actively supports organizations and events committed to the advancement of cancer research and patient support. Its cancer treatment decision support offering, TreatmentMAP™, uses molecular data from a patient’s tumor and advanced proprietary analytics to recommend the safest, most effective treatment options for their cancer, promoting personalized, precision medicine.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.